Innate Pharma Files 6-K Report

Ticker: IPHA · Form: 6-K · Filed: Apr 23, 2026 · CIK: 0001598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHA)
Form Type6-K
Filed DateApr 23, 2026
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: foreign-issuer, regulatory-filing, corporate-update

TL;DR

Innate Pharma filed a 6-K on 4/23/26, check EX-99.1 for details.

AI Summary

Innate Pharma SA filed a 6-K report on April 23, 2026. The filing includes a document titled 'EX-99.1' and a complete submission text file. The company's mailing and business address is in Marseille, France.

Why It Matters

This filing provides an update on Innate Pharma's regulatory activities and corporate information, which is important for investors tracking the company's compliance and operational status.

Risk Assessment

Risk Level: low — A 6-K filing is a routine report for foreign issuers and typically does not contain material non-public information that would significantly alter an investment decision.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of a 6-K filing?

A 6-K filing is a report of a foreign issuer required by SEC rules 13a-16 and 15d-16, used to submit information that the company makes or is required to make public in its home country.

What specific documents are included in this 6-K filing?

This filing includes a 6-K document (a6k-iphx260423.htm) and an exhibit labeled EX-99.1 (exhibit991-260423.htm), along with a complete submission text file.

Where is Innate Pharma SA located?

Innate Pharma SA's mailing and business address is 117 Avenue de Luminy BP 30191, Marseille, France.

What is the CIK number for Innate Pharma SA?

The CIK number for Innate Pharma SA is 0001598599.

What is the SIC code associated with Innate Pharma SA?

The SIC code is 2836, which corresponds to Biological Products, (No Diagnostic Substances).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2026 regarding Innate Pharma SA (IPHA).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing